“…DISCLOSURES: Khurram Rana, PharmD, Entasis Therapeutics (Employee) Galia Rahav, MD, AstraZeneca (Scientific Research Study Investigator) Kathleen Maloney, CCRP, Entasis Therapeutics (Employee) Subasree Srinivasan, MD MPH, Entasis therapeutics (Employee)…”
Enlace del recurso
Enlace del recurso

“…BACKGROUND: Several cases of unusual thrombotic events and thrombocytopenia have developed after vaccination with the recombinant adenoviral vector encoding the spike protein antigen of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (ChAdOx1 nCov-19, AstraZeneca). More data were needed on the pathogenesis of this unusual clotting disorder. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…The refusal rate (RR) after 15th March (date of AstraZeneca-AZD1222 suspension) was more than doubled compared with the RR observed before (19.7% versus 8.6%, odds ratio [OR] 2.60, 95% CI 1.69–3.99; P < 0.0001). …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Moreover, 38.9% of survey participants revealed that they would like to take a COVID-19 vaccine other than AstraZeneca whereas 61.1% of respondents replied that they do not want to take any kind of COVID-19 vaccine. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…BACKGROUND: The COVID‐19 vaccine from AstraZeneca (AZD1222) is one of several vaccines introduced to provide immunity against SARS‐CoV‐2. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Methods: Sixty-nine recipients of BNT162b2 (Pfizer/BioNTech) and 55 recipients of AZD1222 (AstraZeneca), without previous infection or immunosuppressive medication, were included in this study. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Here, we used the Office for National Statistics COVID-19 Infection Survey—a large community-based survey of individuals living in randomly selected private households across the United Kingdom—to assess the effectiveness of the BNT162b2 (Pfizer–BioNTech) and ChAdOx1 nCoV-19 (Oxford–AstraZeneca; ChAdOx1) vaccines against any new SARS-CoV-2 PCR-positive tests, split according to self-reported symptoms, cycle threshold value (<30 versus ≥30; as a surrogate for viral load) and gene positivity pattern (compatible with B.1.1.7 or not). …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Methodology Participants were adults (Omani citizens and non-citizens) who received AstraZeneca (AZ) or Pfizer (PF) vaccines from primary care facilities in Muscat and were randomly selected from the health information system. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…DESCRIPTION: Nous rapportons un cas de syndrome néphrotique survenant après une première dose vaccinale anti SARS-CoV-2 (ChAdOx1 nCoV-19, Astra-Zeneca®). MÉTHODES: Un homme de 44 ans, sans antécédents médicaux, a été hospitalisé pour un tableau d’anasarque d’installation brutale survenant 3 semaines après une première dose vaccinale. …”
Enlace del recurso
Enlace del recurso

“…RESULTS: 208 patients followed in a single ACHD tertiary centre (33.3 [26–45] years, 54% male) received COVID-19 vaccine, 65% vaccinated at our institution: 199 (96%) received Pfizer–BioNTech BNT162b2 vaccine, 4 (2%) Moderna-1273 and 5 (2%) AstraZeneca–ChAdOx1. Median follow-up after vaccination was 79 [57–96] days. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…A two-dose regimen of the Oxford-AstraZeneca (ChAdOx1) Covid-19 vaccine with an inter-dose interval of three months has been implemented in many countries with restricted vaccine supply. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Au Maroc, les autorités ont opté pour deux vaccins : Sinopharm (Wuhan) et AstraZeneca. Le CNTSH a mis en place de nouveaux critères de don de sang après vaccination COVID-19 (Tableau 2). …”
Enlace del recurso
Enlace del recurso

“…RESULTS: Between 22 January 2021 and 10 June 2021, 3 740 066 Hungarian individuals received two doses of the BNT162b2 (Pfizer-BioNTech), HB02 (Sinopharm), Gam-COVID-Vac (Sputnik-V), AZD1222 (AstraZeneca), or mRNA-1273 (Moderna) vaccines. Incidence rates of SARS-CoV-2 infection and COVID-19-related death were 1.73–9.3/100 000 person-days and 0.04–0.65/100 000 person-days in the fully vaccinated population, respectively. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…This study, as part of the global CoVaST project, aimed to assess the occurrence of short-term adverse events (SRAEs) of two most administered COVID-19 vaccines, mRNA-based (Pfizer-BioNTech and Moderna) and viral vector-based (AstraZeneca) in healthcare sector workers (HWs). Methods: A cross-sectional survey-based study was carried out for the first time among 317 Polish healthcare sector personnel and medical students using a validated and pre-tested questionnaire. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…METHODS: We conducted a prospective observational study in 1,072,313 UK CSS participants who were asymptomatic when vaccinated with Pfizer-BioNTech mRNA vaccine (BNT162b2) or Oxford-AstraZeneca adenovirus-vectored vaccine (ChAdOx1 nCoV-19) between 8 December 2020 and 17 May 2021, who subsequently reported symptoms within seven days (N=362,770) (other than local symptoms at injection site) and were tested for SARS-CoV-2 (N=14,842), aiming to differentiate vaccination side-effects per se from superimposed SARS-CoV-2 infection. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Here, we examine the sensitivity of variants of concern (VOCs) representative of the B.1.617.1 and B.1.617.2 (first associated with infections in India) and B.1.351 (first associated with infection in South Africa) lineages of SARS-CoV-2 to neutralisation by sera from individuals vaccinated with the BNT162b2 (Pfizer/BioNTech) and ChAdOx1 (Oxford/AstraZeneca) vaccines. Across all vaccinated individuals, the spike glycoproteins from B.1.617.1 and B.1.617.2 conferred reductions in neutralisation of 4.31 and 5.11-fold respectively. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…DISCLOSURES: Jacquie Toia, DNP, RN, APN, QarTek (Board Member) Ravi Jhaveri, MD, AstraZeneca (Consultant)Dynavax (Consultant)Elsevier (Other Financial or Material Support, Editorial Stipend as Co-editor in Chief, Clinical Therapeutics)Seqirus (Consultant)…”
Enlace del recurso
Enlace del recurso

“…However, the adenovirus-vector based Oxford/AstraZeneca [ChAdOx1] (AZ) and Johnson & Johnson [Ad26.CoV2.S] COVID-19 vaccines have been linked with serious thromboembolic events combined with thrombocytopenia, denominated Vaccine-induced Immune Thrombocytopenia and Thrombosis (VITT). …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…BACKGROUND: On 8th April 2021, the Australian Technical Advisory Group on Immunisation (ATAGI) made the Pfizer-BioNtech (Comirnaty) vaccine the “preferred” vaccine for adults in Australia aged < 50 years due to a risk of thrombosis with thrombocytopenia syndrome (TTS) following AstraZeneca vaccination. We sought to understand whether this impacted COVID-19 vaccine intentions. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Le vaccin le plus incriminé était AstraZeneca (n = 8), suivi par Pfizer (n = 3) et Janssen (n = 1). …”
Enlace del recurso
Enlace del recurso